DBV Technologies S.A. — Proxy Solicitation & Information Statement 2022

Apr 26, 2022

DEFA14A 1 d263764ddefa14a.htm DEFA14A DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

DBV Technologies S.A.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

DBV TECHNOLOGIES—LIST OF CANDIDATES AS DIRECTORS AGM—MAY 12, 2022

MICHEL DE ROSEN Chairman of the Board & Independent Director Chairman of the Compensation Committee & member of the Nominating and Governance Committee Born on 02/18/1951 in Paris, France Business address : DBV Technologies, 177/181 avenue Pierre Brossolette, 92120 Montrouge (France) Other mandates and positions exercised over the past five years (excluding DBV Technologies) Chairman of the Board of Faurecia SA Chairman of the Board and then director of Pharnext SA CEO of Eutelstat Communications SA Director of Idorsia Pharmaceuticals. Shareholding 23,570 directly held shares 9,000 « BSA 2018 » giving the right to purchase 9,000 shares 6,837 « BSA 2021 » giving the right to purchase 6,837 shares

TIMOTHY E. MORRIS Independent Director and member of the Audit Committee Born on 10/06/1961 in California Business address : DBV Technologies, 177/181 avenue Pierre Brossolette, 92120 Montrouge (France) Other mandates and positions exercised over the past five years (excluding DBV Technologies) Chief Operating Officer and Chief Financial Officer at Humanigen Director of Univercells SA Director of Humanetics Corporation Director, Chair of the Audit Committee and member of the Compensation Committee at Humanigen Chief Financial Officer at Iovance Biotherapeutics Chief Financial Officer at AcelRx Shareholding 6,837 « BSA 2021 » giving the right to purchase 6,837 shares

DANIEL B. SOLAND Independent Director & member of the Compensation Committee Born on 04/24/1958 in Iowa (USA) Business address: DBV Technologies, 177/181 avenue Pierre Brossolette, 92120 Montrouge (France) Other mandates and positions exercised over the past five years (excluding DBV Technologies) Chief Operating Officer at Idera Pharmaceuticals Director of Acadia Pharmaceutical Inc. Director of Kalvista Pharmaceutical Inc. CEO of uniQure N.V Director of Viropharma Inc. Director of Oxford Biomedica PLC Shareholding 5,000 directly held shares 7,500 « BSA 2015 » giving the right to purchase 7,500 shares 10,000 « BSAX 2015 » giving the right to purchase 10,000 shares 7,000 « BSA 2016 » giving the right to purchase 7,000 shares 7,000 « BSA 2018 » giving the right to purchase 7,000 shares 6,837 « BSA 2021 » giving the right to purchase 6,837 shares